about
Thrombosis and cancer: emerging data for the practicing oncologist.Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome.Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study.Catastrophic relapse of Evans syndrome five years after allogeneic BMT notwithstanding full donor chimerism. Terminal hemolytic-uremic syndrome.Cancer, thrombosis and heparin-induced thrombocytopenia.Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies.Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies.International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.Further characterization of platelet-aggregating cysteine proteinase activity in thrombotic thrombocytopenic purpura.Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.Pathogenesis of thrombosis in patients with malignancy.Cancer and venous thromboembolism.Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia.FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factorBiological and clinical aspects of anticancer effects of antithrombotics.Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonatesVenous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).Anticoagulants and cancer survival.American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.Heparin in tumor progression and metastatic dissemination.A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.Hemostatic complications of angiogenesis inhibitors in cancer patients.The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment.Overview of the postulated mechanisms linking cancer and thrombosis.Procoagulant mechanisms in tumour cells.Thrombosis associated with angiogenesis inhibitors.Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party.Activation of clotting factors in cancer.Management of venous thromboembolism in cancer patients: ESMO clinical recommendations.Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).Venous thromboembolism in the hematologic malignancies.Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemiaEpidemiology, risk and outcomes of venous thromboembolism in cancer.Anticancer treatment and thrombosis.Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.Mechanisms of thrombosis in cancer.Myeloproliferative neoplasms and thrombosis.The coagulopathy of cancer.
P50
Q30634786-E9B6FCE7-E61A-4730-BBDE-162D0B6E059FQ33355009-D668998B-9329-4ADC-9EDD-D3EE88F013CCQ33366745-2DA1E7C9-6580-4684-A6A6-856173C0A961Q33373065-7086BDD2-9688-44EE-AFB1-5CBB02F8437AQ33377449-299EA08F-C07C-4C19-8011-94D2679C94AAQ33377454-5C117F31-8C37-4173-972D-E9AFAC4609BBQ33377479-A1749B73-1E6C-49AF-A9DD-4E28698E1421Q33399611-4235540E-9C86-4250-BDC3-7215298A79CBQ33404714-DE6242F9-02F4-4AFA-99D4-DBD48BCA5133Q33491059-B45DC584-65D8-4C60-A5BC-D695FE243742Q33561213-30980ED7-FF80-498D-97B0-C922C38C2980Q34261270-A2FEB221-B335-43B4-900C-CC5566692E53Q34422539-BB05944B-C34C-495E-966A-0534CD5EC025Q35205511-3311ED33-6D85-4D5D-A176-DBB7591CB70DQ35999309-07BBFD65-80A2-4304-863C-0CFAE555653DQ36030515-C5DCEB5F-4001-4810-9007-115E9A12BAEFQ36220059-99CE96F8-C8A7-461B-B492-3FEB475EE5D7Q36534495-3195B63F-83F9-4337-80E5-6F6258DE123CQ36685178-4DE04345-2902-4F44-9E3F-4BC97E23CAD4Q36984787-1B14F75D-0770-4C78-B257-C4C69527806DQ37000500-D0EEE932-C2FA-43F4-A559-894AAA19AE27Q37091111-FFEB5C13-D090-49FD-80BE-68DC7D6E29FFQ37246729-1BAACEE5-7540-46A6-848A-B29B7D958E7FQ37279978-5BC58322-5709-4203-B2C0-B5C49A41D430Q37374557-5A2DD06B-380D-42A9-A65D-E9E6FAB1FBCFQ37379700-15EBFB4A-2BF0-4AAD-B2F1-B44FD634C6FCQ37414578-00008D0B-31FF-4663-BDC6-23D4AF03859EQ37414595-EB37BC4F-2B09-4314-BCB2-B97E54BBB101Q37417311-D812E4D3-6BEF-4519-8393-BDE20C821A00Q37450938-0FF885A9-F031-411F-A94D-4B80AD88F089Q37489073-B39EDC0C-FB87-4D15-BB60-CD9479DAEA75Q37595071-778BB2F9-CCDB-46A5-A6BC-85E53E3208D6Q37596805-35EC9551-7A5A-4F5D-B860-6E0F040064CAQ37625070-4025D42D-F7D4-4774-83D8-31BFFDB78205Q37942468-85195B96-B7FA-4C80-9FAB-EC19FC0F4F9EQ37961377-3CC80FFF-BFA1-4BCB-949F-5E53670ABF74Q37973346-E3F35C55-F68F-408E-914F-E9C92F8D2A25Q38085785-AB03DF30-D517-48E6-93C3-CD971D2DA212Q38119076-58CAC33C-2C21-40E0-BD6B-8308AF03FF12Q38233153-0113773C-17A5-466E-B5B5-5CA1D1EB9883
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anna Falanga
@ast
Anna Falanga
@en
Anna Falanga
@es
Anna Falanga
@nl
Anna Falanga
@sl
type
label
Anna Falanga
@ast
Anna Falanga
@en
Anna Falanga
@es
Anna Falanga
@nl
Anna Falanga
@sl
prefLabel
Anna Falanga
@ast
Anna Falanga
@en
Anna Falanga
@es
Anna Falanga
@nl
Anna Falanga
@sl
P106
P1153
7006586115
P21
P31
P496
0000-0002-5007-3457